Skip to main content Skip to search Skip to main navigation

CDSCO: Indian Agency Drafts Revised GDP Guidelines

The Central Drugs Standard Control Organization (CDSCO), the Ministry of Health, and the Government of India have released a 25-page document Draft Guidelines on GDP for Pharmaceutical Products. The guidelines have been developed following WHO TRS 1025 Annex 7: Good Storage and Distribution Practices for Medical Products, with a broader focus on pharmaceutical product storage.

These guidelines aim to ensure the quality and identity of pharmaceutical products during all aspects of the distribution process. Aspects include organization management, personnel, quality systems, premises, temperature, environmental and storage control, transportation, shipment containers and labeling, dispatch and receipt, documentation, complaints, recalls and returns, handling spurious products, importation, contract activities, and self-inspection.

It applies to all entities involved in different stages of the supply chain of medical products, manufacturers and wholesalers, as well as brokers, suppliers, distributors, logistics providers, traders, transport companies and forwarding agents and their employees.

A 30-day comment period on the draft guidance has started on 9 August 2024.


Source:

WHO: TRS 1025 – Annex 7: Good storage and distribution practices for medical products

CDSCO: Draft guidelines on GDP for pharmaceutical products

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next